These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

101 related items for PubMed ID: 16762511

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Muraglitazar (Bristol-Myers Squibb/Merck).
    Barlocco D.
    Curr Opin Investig Drugs; 2005 Apr; 6(4):427-34. PubMed ID: 15898350
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Selling safety--lessons from muraglitazar.
    Brophy JM.
    JAMA; 2005 Nov 23; 294(20):2633-5. PubMed ID: 16239638
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Assessment of dose proportionality of muraglitazar after repeated oral dosing in rats via a sparse sampling methodology.
    Yao M, Swaminathan A, Srinivas N.
    Biopharm Drug Dispos; 2007 Jan 23; 28(1):35-42. PubMed ID: 17117455
    [Abstract] [Full Text] [Related]

  • 13. Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling.
    Zhang D, Wang L, Raghavan N, Zhang H, Li W, Cheng PT, Yao M, Zhang L, Zhu M, Bonacorsi S, Yeola S, Mitroka J, Hariharan N, Hosagrahara V, Chandrasena G, Shyu WC, Humphreys WG.
    Drug Metab Dispos; 2007 Jan 23; 35(1):150-67. PubMed ID: 17062777
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Involvement of multiple cytochrome P450 and UDP-glucuronosyltransferase enzymes in the in vitro metabolism of muraglitazar.
    Zhang D, Wang L, Chandrasena G, Ma L, Zhu M, Zhang H, Davis CD, Humphreys WG.
    Drug Metab Dispos; 2007 Jan 23; 35(1):139-49. PubMed ID: 17062778
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Optimization to eliminate the interference of migration isomers for measuring 1-O-beta-acyl glucuronide without extensive chromatographic separation.
    Xue YJ, Akinsanya JB, Raghavan N, Zhang D.
    Rapid Commun Mass Spectrom; 2008 Jan 23; 22(2):109-20. PubMed ID: 18059002
    [Abstract] [Full Text] [Related]

  • 20. Muraglitazar: beneficial or detrimental in the treatment of Type 2 diabetes?
    Doggrell SA.
    Expert Opin Pharmacother; 2006 Jun 23; 7(9):1229-33. PubMed ID: 16732709
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.